Payment overview · 2025
General Payments
$1,288.08
51 reported records · 22 companies
Healthcare provider profile · identity verified
Tejas Patel, MD
Allopathic & Osteopathic Physicians|Internal Medicine|Nephrology · LAKE SUCCESS, NY · NPI 1467421032
Verified facts
What the public records show
CMS Open Payments records show Tejas Patel, MD received $1,288.08 in general payments during 2025 across 51 reported records.
Novartis Pharmaceuticals Corporation accounted for 13.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 29 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Mounjaro, Ozempic, Rayaldee, Veltassa.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Synthroid by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 107 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 107 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Mounjaro by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 62 claims for Ozempic by this doctor in 2024.
OPKO Pharmaceuticals, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported RAYALDEE as an associated drug or biological on 5435 records involving 1739 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Rayaldee by this doctor in 2024.
Vifor Pharma, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Veltassa as an associated drug or biological on 5970 records involving 2480 distinct recipient NPIs. Public Medicare Part D data also shows 71 claims for Veltassa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $178.40 | 13.8% | 10 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $158.52 | 12.3% | 2 | 2025 |
| Travere Therapeutics, Inc. | Unresolved — no canonical attribution shown | $141.49 | 11.0% | 6 | 2025 |
| Recor Medical Inc | Unresolved — no canonical attribution shown | $138.92 | 10.8% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $112.30 | 8.7% | 5 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $76.59 | 6.0% | 4 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $67.39 | 5.2% | 3 | 2025 |
| SCPHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $66.54 | 5.2% | 3 | 2025 |
| OPKO Pharmaceuticals, LLC | Unresolved — no canonical attribution shown | $48.87 | 3.8% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $39.09 | 3.0% | 2 | 2025 |
| Mallinckrodt Hospital Products Inc. | Unresolved — no canonical attribution shown | $28.80 | 2.2% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $26.86 | 2.1% | 1 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $25.01 | 1.9% | 1 | 2025 |
| Amneal Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $25.00 | 1.9% | 1 | 2025 |
| Madrigal Pharmaceuticals | Unresolved — no canonical attribution shown | $24.24 | 1.9% | 1 | 2025 |
| CONMED Corporation | Unresolved — no canonical attribution shown | $23.65 | 1.8% | 1 | 2025 |
| Fresenius USA Manufacturing, Inc. | Unresolved — no canonical attribution shown | $23.13 | 1.8% | 1 | 2025 |
| Rhythm Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $19.94 | 1.6% | 1 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $16.46 | 1.3% | 1 | 2025 |
| Dynavax Technologies Corporation | Unresolved — no canonical attribution shown | $15.96 | 1.2% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $15.90 | 1.2% | 1 | 2025 |
| Vifor Pharma, Inc. | Unresolved — no canonical attribution shown | $15.02 | 1.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,288.08 | 51 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $173.92 | 3 | 2025 |
Source payment records
|
|||||
| Paradise Ultrasound Renal Denervation System Normalized: paradise ultrasound renal denervation system |
Device | Recor Medical Inc | $138.92 | 1 | 2025 |
Source payment records
|
|||||
| Fabhalta Normalized: fabhalta |
Drug | Novartis Pharmaceuticals Corporation | $102.81 | 5 | 2025 |
Source payment records
|
|||||
| Vanrafia Normalized: vanrafia |
Drug | Novartis Pharmaceuticals Corporation | $82.48 | 4 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $75.59 | 5 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $70.25 | 3 | 2025 |
Source payment records
|
|||||
| FUROSCIX Normalized: furoscix |
Drug | SCPHARMACEUTICALS INC. | $66.54 | 3 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $61.19 | 3 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $50.06 | 2 | 2025 |
Source payment records
|
|||||
| RAYALDEE Normalized: rayaldee |
Drug | OPKO Pharmaceuticals, LLC | $48.87 | 3 | 2025 |
Source payment records
|
|||||
| KRYSTEXXA Normalized: krystexxa |
Biological | Amgen Inc. | $42.05 | 2 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $39.09 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $36.67 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $30.72 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $30.72 | 1 | 2025 |
Source payment records
|
|||||
| ACTHAR Normalized: acthar |
Biological | Mallinckrodt Hospital Products Inc. | $28.80 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $26.86 | 1 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $25.01 | 1 | 2025 |
Source payment records
|
|||||
| UNITHROID Normalized: unithroid |
Drug | Amneal Pharmaceuticals LLC | $25.00 | 1 | 2025 |
Source payment records
|
|||||
| REZDIFFRA Normalized: rezdiffra |
Drug | Madrigal Pharmaceuticals | $24.24 | 1 | 2025 |
Source payment records
|
|||||
| CONMED BILIARY Normalized: conmed biliary |
Device | CONMED Corporation | $23.65 | 1 | 2025 |
Source payment records
|
|||||
| VELPHORO Normalized: velphoro |
Drug | Fresenius USA Manufacturing, Inc. | $23.13 | 1 | 2025 |
Source payment records
|
|||||
| IMCIVREE Normalized: imcivree |
Drug | Rhythm Pharmaceuticals, Inc. | $19.94 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $19.17 | 1 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $16.46 | 1 | 2025 |
Source payment records
|
|||||
| Heplisav-B Normalized: heplisav b |
Drug | Dynavax Technologies Corporation | $15.96 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $15.90 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $15.90 | 1 | 2025 |
Source payment records
|
|||||
| Veltassa Normalized: veltassa |
Drug | Vifor Pharma, Inc. | $15.02 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 107 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 20 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 62 | exact normalized | Medicare Part D |
| RAYALDEE rayaldee |
2025 | Rayaldee | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Veltassa veltassa |
2025 | Veltassa | 2024 | 71 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
107 | 38 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
107 | 38 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
62 | 13 |
| OPKO Pharmaceuticals, LLC Exact reporting entity; no affiliate inference |
2025 | RAYALDEE open payments reported associated product |
CMS Open Payments — General Payments 5435 supporting records · 1739 recipient NPIs · example record 1222072234 |
Rayaldee · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Vifor Pharma, Inc. Exact reporting entity; no affiliate inference |
2025 | Veltassa open payments reported associated product |
CMS Open Payments — General Payments 5970 supporting records · 2480 recipient NPIs · example record 1172020739 |
Veltassa · 2024 Exact normalized brand match · 1 Part D row |
71 | 27 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 258 | 115 |
| Atorvastatin Calcium | Atorvastatin Calcium | 196 | 76 |
| Losartan Potassium | Losartan Potassium | 158 | 60 |
| Farxiga | Dapagliflozin Propanediol | 130 | 45 |
| Furosemide | Furosemide | 121 | 50 |
| Carvedilol | Carvedilol | 116 | 28 |
| Allopurinol | Allopurinol | 114 | 43 |
| Jardiance | Empagliflozin | 107 | 38 |
| Valsartan | Valsartan | 93 | 39 |
| Gabapentin | Gabapentin | 72 | 23 |
| Hydralazine Hcl | Hydralazine Hcl | 71 | 24 |
| Tamsulosin Hcl | Tamsulosin Hcl | 71 | 30 |
| Veltassa | Patiromer Calcium Sorbitex | 71 | 27 |
| Metoprolol Succinate | Metoprolol Succinate | 66 | 28 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 66 | 33 |
| Omeprazole | Omeprazole | 64 | 18 |
| Pantoprazole Sodium | Pantoprazole Sodium | 64 | 24 |
| Ozempic | Semaglutide | 62 | 13 |
| Metformin Hcl | Metformin Hcl | 61 | 25 |
| Torsemide | Torsemide | 59 | 23 |
| Levothyroxine Sodium | Levothyroxine Sodium | 55 | 21 |
| Azithromycin | Azithromycin | 41 | 36 |
| Lisinopril | Lisinopril | 40 | 14 |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 39 | 15 |
| Hydrochlorothiazide | Hydrochlorothiazide | 39 | 20 |
| Spironolactone | Spironolactone | 39 | 11 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 37 | 32 |
| Finasteride | Finasteride | 36 | 13 |
| Alprazolam | Alprazolam | 34 | 19 |
| Cephalexin | Cephalexin | 34 | 29 |
| Glipizide Er | Glipizide | 34 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 34 | 11 |
| Escitalopram Oxalate | Escitalopram Oxalate | 31 | 16 |
| Fluticasone Propionate | Fluticasone Propionate | 30 | suppressed |
| Potassium Chloride | Potassium Chloride | 30 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 28 | suppressed |
| Glimepiride | Glimepiride | 28 | 11 |
| Simvastatin | Simvastatin | 28 | 12 |
| Pravastatin Sodium | Pravastatin Sodium | 26 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 25 | 23 |
| Potassium Citrate Er | Potassium Citrate | 25 | suppressed |
| Bumetanide | Bumetanide | 24 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 24 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 24 | suppressed |
| Famotidine | Famotidine | 23 | suppressed |
| Atenolol | Atenolol | 22 | suppressed |
| Calcitriol | Calcitriol | 21 | 11 |
| Lokelma | Sodium Zirconium Cyclosilicate | 21 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 21 | suppressed |
| Prednisone | Prednisone | 21 | suppressed |
| Ramipril | Ramipril | 21 | suppressed |
| Januvia | Sitagliptin Phosphate | 20 | suppressed |
| Mounjaro | Tirzepatide | 20 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 20 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 18 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 18 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 18 | 13 |
| Diazepam | Diazepam | 17 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 17 | suppressed |
| Eplerenone | Eplerenone | 17 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 17 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 16 | suppressed |
| Synthroid | Levothyroxine Sodium | 16 | suppressed |
| Nifedipine Er | Nifedipine | 15 | suppressed |
| Clonazepam | Clonazepam | 14 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 14 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 14 | suppressed |
| Colchicine | Colchicine | 13 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 13 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 13 | suppressed |
| Sevelamer Carbonate | Sevelamer Carbonate | 13 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 12 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 12 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 12 | suppressed |
| Rayaldee | Calcifediol | 12 | suppressed |
| Repaglinide | Repaglinide | 12 | suppressed |
| Repatha Sureclick | Evolocumab | 12 | suppressed |
| Steglatro | Ertugliflozin Pidolate | 12 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 12 | suppressed |
| Eliquis | Apixaban | 11 | suppressed |
| Ezetimibe | Ezetimibe | 11 | suppressed |
| Febuxostat | Febuxostat | 11 | suppressed |
| Irbesartan | Irbesartan | 11 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 11 | suppressed |
| Pregabalin | Pregabalin | 11 | suppressed |
| Sodium Polystyrene Sulfonate | Sodium Polystyrene Sulfonate | 11 | suppressed |
| Sps | Sodium Polystyrene Sulfon/Sorb | 11 | suppressed |
| Vancomycin Hcl | Vancomycin Hcl | 11 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 11 | suppressed |
| Xarelto | Rivaroxaban | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,288.08 · 51 records | Novartis Pharmaceuticals Corporation | ACTHAR, AREXVY, CONMED BILIARY, FREESTYLE LIBRE 3, FUROSCIX, Fabhalta, Heplisav-B, IBSRELA, IMCIVREE, JARDIANCE, KRYSTEXXA, LEQVIO, MOUNJARO, NEXLETOL, OTEZLA, Ozempic, Paradise Ultrasound Renal Denervation System, RAYALDEE, REPATHA, REZDIFFRA, Rybelsus, SHINGRIX, UNITHROID, VELPHORO, VRAYLAR, Vanrafia, Veltassa, Wegovy, ZEPBOUND | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error